HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
Breast Cancer Update
00:00
How do sacituzumab and datopotamab compare on tolerability and selection?
Dr Huppert contrasts SG and Dato‑DXd side effects, schedules, OS data nuances, and factors guiding agent choice.
Play episode from 09:31
Transcript
